FLC
IKT icon

Fifth Lane Capital’s Inhibikase Therapeutics IKT Stock Holding History

Fifth Lane Capital’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,896
Closed -$41.8K – 29
2026
Q1 		$41.8K Buy
+24,896
New +$44.2K 0.05% 55

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fifth Lane Capital's IKT Position: Q2 2026 in Review

Fifth Lane Capital sold out of Inhibikase Therapeutics (IKT) in Q2 2026, closing a stake of 24,896 shares — an estimated $41.8K sold.

Fifth Lane Capital first reported a position in IKT in Q1 2026 and held it in 1 quarter. The position peaked at $41.8K in Q1 2026. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

  • Fifth Lane Capital reported no remaining Inhibikase Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Fifth Lane Capital sold 24,896 Inhibikase Therapeutics shares in Q2 2026, an estimated $41.8K.
  • Fifth Lane Capital first reported a position in Inhibikase Therapeutics in Q1 2026 and held it in 1 quarter.
  • Fifth Lane Capital's Inhibikase Therapeutics position peaked at $41.8K in Q1 2026.
  • 106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Fifth Lane Capital's 13F filing for Q2 2026, filed 6 Aug 2026.